TIME until DEADLINE travel grant application.
submit your abstract today!

REGISTRATION IS OPEN NOW!
On 12- 14 November 2019 ReSViNET Foundation will host its 5th conference: “RSVVW 2019 - A Global Conference on Novel RSV Preventive and Therapeutic Interventions" in Accra, Ghana. ​
ReSViNET Foundation is certified by NGOsource as equivalent to a U.S. public charity!

NEws

Recent RESVINET PUBLICATIONs

EXPERT CONSENSUS ON PALIVIZUMAB USE FOR RESPIRATORY SYNCYTIAL VIRUS IN DEVELOPED COUNTRIES
Sánchez Luna M, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A, Chawla R, Dotta A, Rodríguez Fernández R, Resch B, Carbonell-Estrany X.
Abstract
Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to costs-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. ..read more

Educational activities

PeerVoice has launched three RSV activities, in collaboration with and endorsed by ReSViNET Foundation. Use the link below for more information and content of the programs.

RESPIRATORY SYNCYTIAL VIRUS AND CHILD PNEUMONIA WEBINAR

Dr. Ting Shi (University of Edinburgh): Global disease burden estimate of RSV in young children
Dr. Marijke Proesmans (Katholieke Universiteit Leuven): RSV therapeutics
Dr. Keith Klugman (Director, Pneumonia, Bill&Melinda Gates Foundation): RSV immunization and future directions
Dr. Louis Bont (Chairman ReSViNET Foundation): RSV clinical presentation and disease severity​
Visual
Use the link below to access the SlideShare presentation for the talks:
https://www.slideshare.net/secret/H0MzMgF2seNUX7
 NOTE: Please download this slide deck from the SlideShare platform to view.
RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. 
Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission with the goal to decrease the global burden of RSV infection through the advancement of research; providing scientific input and involvement in clinical trials. ReSViNET Foundation is a financially and otherwise independent regulated entity.

ABOUT RESVINET FOUNDATION

PAPER OF THE MONTH

A do-it-yourself toolbox to make an RSV vaccine
Jessica Marcandalli, Brooke Fiala, Sebastian Ols, Karin Loré, Laurent Perez, Neil P. King
​
Self-assembling proteins are promising inducers of a strong antibody response, because they enable multivalent antigen presentation. Jessica Marcandalli and colleagues designed such a self-assembling protein nanoparticle vaccine, based on prefusion-stabilized RSV-F antigen. It is a computational vaccine that consists of multiple nanoparticles fused to 20 pre-F trimers, resulting in a high density of pre-F antigens. The study shows a 10 fold higher neutralizing antibody response in mice and non-human primates, compared to the response to trimeric form of RSV-pre-F protein.
Marcandalli et al. hereby offer a new do-it-yourself protocol to customize RSV structure-based vaccines. With this ever expanding RSV vaccine development - toolbox we are getting closer to finding a suitable RSV-vaccine every day. 

ReSViNET Global partners